Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.92 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA7 | P43166 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | GPR183 | P32249 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21590292 | 0.98 | HPGD (0.89) | HPGDPOLBALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL971083 | 0.96 | HPGD (1.00) | HPGDPOLBALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL24185725 | 0.94 | HPGD (0.96) | HPGDPOLBALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL969583 | 0.94 | HPGD (0.96) | HPGDPOLBALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL17465272 | 0.88 | POLB (1.00) | HPGDPOLBALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL2095174 | 0.84 | HPGD (0.72) | HPGDPOLBALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL969802 | 0.84 | HPGD (0.72) | HPGDPOLBALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL10721733 | 0.84 | HPGD (0.95) | HPGDALDH1A1L3MBTL3L3MBTL1CA12 | |
| SCHEMBL28067455 | 0.84 | HPGD (0.72) | HPGDPOLBALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL6595655 | 0.84 | HPGD (0.72) | HPGDPOLBALDH1A1L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| WO-2022253311-A1 | HPK1 INHIBITOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253311-A1 | HPK1 INHIBITOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-12-08 | — | — | WO | disclosed |
| CN-115433184-A | HPK1 inhibitor and application thereof | 武汉人福创新药物研发中心有限公司 | 2022-12-06 | — | — | CN | disclosed |
| EP-3265453-B1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | BOEHRINGER INGELHEIM INT (DE) | 2022-06-29 | — | — | EP | disclosed |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
| WO-2016112863-A1 | N-SUBSTITUTED-3,5-DISUBSTITUTED BENZAMIDE COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | 中国科学院上海药物研究所 | 2016-07-21 | — | — | WO | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| CN-101282966-A | Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes | ASTRAZENECA AB (SE) | 2008-10-08 | — | — | CN | disclosed |
| EP-1945628-A1 | NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER'S DISEASE | AstraZeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| EP-1915367-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007040440-A1 | NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER’S DISEASE | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007040440-A1 | NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER’S DISEASE | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007017649-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, MAPKAPK2, MAP3K20 | HPGD 4226/4885POLB 1388/4885ALDH1A1 4878/4885 |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BRD9, BRD1, BRD2 | HPGD 721/4885POLB 914/4885ALDH1A1 2654/4885 |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BRD9, BRD1, BRD2 | HPGD 534/4885POLB 958/4885ALDH1A1 2461/4885 |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | HPGD 1376/4885POLB 4200/4885ALDH1A1 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.